Resume of Yuanbao Ai

Basic Information



School : Gender: Date of Birth: Title: Education: Tutor: E-mail Interest of research:

School of Life and Health Science male 199012 Lecturer Ph.D of Science Master degree 20231030@hbut.edu.cn Covalent molecule drug research, human monoclonal antibody research

Academic Background

From September 2009 to July 2013, Wuhan Polytechnic University, Bachelor's degree in Pharmaceutical Engineering;

From September 2013 to July 2016, China Three Gorges University, Master's degree of Pharmacology;

From September 2018 to July 2021, JINAN University, Ph.D of Science.

Enrollment Information

- 1. Enrollment Discipline: Master of Biotechnology
- 2. Research direction: Covalent molecule drug research
- 3. Enrollment Year: 2023-2024

Representative Projects

1. Hubei University of Technology Scientific Research Initiation Fund Project, "Covalent inhibitor discovery study based on SCARdock", XJ2023009701, Project leader.

2. Hubei Province Innovation Group Project, "Mechanism of regulation and intervention of key proteins in the regulatory network of polyamine metabolism in tumour cells", 2024AFA014, Participant.

Representative Articles

1. Yuanyuan Li*†, Siyu Tian†, **Yuanbao Ai**†, ... Jing Jin*. (2024). A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates, Frontiers in Immunology, Volume 15.

2. Li, Y., Zhang, Y., Zhou, Y., Li, Y., Xu, J., Ai, Y., ... & Jin, J. (2023). An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques. Signal Transduction and Targeted Therapy, 8(1), 173.

3. Ai, Y., Wu, C., Zhang, M., Jaijyan, D. K., Liu, T., Zan, L., ... & Liao, H. X. (2022).

Neutralization epitopes in trimer and pentamer complexes recognized by potent cytomegalovirus-neutralizing human monoclonal antibodies. Microbiology Spectrum, 10(6), e01393-22.

4. Ai, Y., Yu, L., Tan, X., Chai, X., & Liu, S. (2016). Discovery of covalent ligands via noncovalent docking by dissecting covalent docking based on a "steric-clashes alleviating receptor (SCAR)" strategy. Journal of Chemical Information and Modeling, 56(8), 1563-1575.

5. Yu, L. L., Li, R. T., Ai, Y. B., Liu, W., Deng, Z. S., & Zou, Z. M. (2014). Protoberberine isoquinoline alkaloids from Arcangelisia gusanlung. Molecules, 19(9), 13332-13341.